Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of thrombocytopenia and icariin, which is applied in the field of medicine, can solve the problems of unsustainable therapeutic effect and easy recurrence of side effects, and achieve the effects of increasing medication compliance, low drug side effects, and definite curative effect
Active Publication Date: 2015-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 7 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0009] In order to overcome the technical deficiencies in the prior art that the treatment effect of the medicine for thrombocytopenia is not long-lasting, the drug is easy to relapse and the side effects are large, the present invention provides a medicine for the treatment of thrombocytopenia, which uses icarigenin as the main active ingredient , when it is used in the treatment of thrombocytopenia, it has the characteristics of definite curative effect, small side effects, and no rebound after drug withdrawal, and is very suitable for clinical use in patients with thrombocytopenia
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0021] Example 1 Icarigenin Injection
[0022] prescription:
[0023] Icarigenin 10mg
[0024] Propylene glycol 3ml
[0025] Ethanol 0.5ml
[0026] Add 0.9% sodium chloride solution to 10ml
[0027] ____________
[0028] Preparation Process:
[0029] Mix the prescribed amount of propylene glycol and ethanol evenly, add icariin, stir to dissolve, add the prescribed amount of 0.9% sodium chloride solution, stir evenly, add 0.5% activated carbon for needles, stir, and decarbonize to obtain the product.
Embodiment 2
[0030] Example 2 Icarigenin Injection
[0031] prescription:
[0032] Icarigenin 10mg
[0033] PEG-400 2ml
[0034] Add 0.9% sodium chloride solution to 10ml
[0035] __________
[0036] Preparation process: add the prescribed amount of PEG-400 to icariin, stir to dissolve, add 0.9% sodium chloride solution to 10ml, stir evenly, add 0.5% activated carbon for needles, stir, and decarbonize to obtain the product.
Embodiment 3
[0037] Example 3 Icarigenin Injection
[0038] prescription:
[0039] Icariin 50mg
[0040] Ethanol 3.5ml
[0041] Tween-80 1.5g
[0042] Add water for injection to 10ml
[0043] Preparation process: Mix the prescribed amount of ethanol and Tween-80 evenly, add icariin, stir to dissolve, add 0.9% sodium chloride solution to 10ml, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize , that is.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.
Description
technical field [0001] The invention relates to a new medical application of icariin, in particular to the application of icariin in the preparation of medicines for treating or preventing thrombocytopenia, and belongs to the field of medicine. Background technique [0002] Thrombocytopenia is a disease caused by decreased platelets in peripheral blood (<100,000 / μl) leading to bleeding in the skin, mucous membranes and internal organs. Violet blood blisters on the mucous membrane and tongue are common clinical diseases characterized by coagulation dysfunction and bleeding. Severe cases can cause massive hemorrhage, which is life-threatening. It accounts for about 30% of bleeding diseases in clinical practice. [0003] The causes of thrombocytopenia can be divided into: (1) Decreased or ineffective death of platelet production: including hereditary and acquired. Acquired thrombocytopenia is caused by certain factors such as drugs, malignant tumors, infections, ionizing rad...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more